Aktionsplan NeuBase Therapeutics, Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. weitere details| IPO date | 2007-05-01 |
|---|---|
| ISIN | US64132K1025 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.neubasetherapeutics.com |
| Цена ао | 0.378 |
| Preisänderung pro Tag: | -0% (0.378) |
|---|---|
| Preisänderung pro Woche: | -0% (0.378) |
| Preisänderung pro Monat: | -0% (0.378) |
| Preisänderung über 3 Monate: | -0% (0.378) |
| Preisänderung über sechs Monate: | -0% (0.378) |
| Preisänderung pro Jahr: | -15.98% (0.4499) |
| Preisänderung über 3 Jahre: | -80.81% (1.97) |
| Preisänderung über 5 Jahre: | -94.71% (7.14) |
| Preisänderung seit Jahresbeginn: | -0% (0.378) |
|
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institutionen | Volumen | Aktie, % |
|---|---|---|
| Greenlight Capital, Inc. | 136350 | 3.63 |
| UBS Group AG | 65724 | 1.75 |
| Point72 Asset Management, L.P. | 62500 | 1.67 |
| Renaissance Technologies, LLC | 56967 | 1.52 |
| Carnegie Mellon University | 46970 | 1.25 |
| Two Sigma Investments, LP | 21083 | 0.56 |
| Vanguard Group Inc | 18981 | 0.51 |
| Kestra Advisory Services, LLC | 16476 | 0.44 |
| Jacob Asset Management Of New York LLC | 15655 | 0.42 |
| Prelude Capital Management LLC | 15550 | 0.41 |
| Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
|---|---|---|---|
| Dr. Dietrich A. Stephan Ph.D. | Founder, President & Director | 836.58k | 1970 (55 Jahre) |
| Mr. Todd P. Branning | Interim CEO, CFO & Secretary | 427.44k | 1970 (55 Jahre) |
Adresse: United States, Pittsburgh. PA, 350 Technology Drive - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.neubasetherapeutics.com
Webseite: https://www.neubasetherapeutics.com
